---
layout: default
title: Palivizumab
parent: 僅模型預測 (L5)
nav_order: 473
evidence_level: L5
indication_count: 10
---

# Palivizumab
{: .fs-9 }

證據等級: **L5** | 預測適應症: **10** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Palivizumab: From RSV Prophylaxis to Benign Neoplasm of Tongue

## One-Sentence Summary

Palivizumab is a monoclonal antibody against the RSV fusion (F) protein, used to prevent respiratory syncytial virus infection in high-risk infants.
The TxGNN model predicts it may be effective for **Benign Neoplasm of Tongue**,
but currently **0 clinical trials** and **0 publications** support this direction, and the model's own rationale text identifies no plausible biological mechanism linking the two.

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | RSV (respiratory syncytial virus) infection prophylaxis (inferred from mechanism-of-action text in the evidence pack; no Taiwan license data exists) |
| Predicted New Indication | Benign Neoplasm of Tongue |
| TxGNN Prediction Score | 99.94% |
| Evidence Level | L5 |
| Saudi Arabia Market Status | 未上市 (Not marketed) |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |

## Why is This Prediction Reasonable?

Detailed mechanism-of-action data from DrugBank is marked as a data gap. However, the evidence pack's own repurposing-rationale notes consistently describe palivizumab as an anti-RSV F-protein monoclonal antibody that neutralizes respiratory syncytial virus — a purely antiviral, receptor-blocking mechanism with no known role in cell proliferation, oncogenesis, or tumour biology.

The original indication (RSV prophylaxis in infants) and the predicted new indication (a benign tongue neoplasm) belong to entirely different disease domains — infectious disease prevention versus a head-and-neck proliferative lesion. There is no shared pathway, receptor, or tissue tropism connecting RSV fusion-protein neutralization to tongue tissue overgrowth.

The rationale text supplied alongside this prediction explicitly states that no causal hypothesis can be constructed, given the missing original MOA data and the absence of any biological overlap. This prediction should therefore be treated as a raw model output (TxGNN embedding similarity) rather than a mechanistically grounded hypothesis. The same pattern holds across all ten ranked predictions for this drug (ranks 1–10, scores 99.94%–99.94%), none of which are supported by trial or literature evidence.

## Clinical Trial Evidence

Currently no related clinical trials registered

## Literature Evidence

Currently no related literature available

## Saudi Arabia Market Information

Palivizumab is not marketed in Taiwan (`market_status: 未上市`, 0 authorizations). No license or product records are available to summarize.

## Safety Considerations

Please refer to the package insert for safety information.

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The prediction is supported only by a raw TxGNN similarity score (L5), with zero clinical trials and zero publications, and the drug's own documented mechanism (RSV F-protein neutralization) offers no plausible link to a tongue neoplasm. The drug is also unmarketed in Taiwan, blocking any local safety review.

**To proceed, the following is needed:**
- Confirmed original MOA and indication data from DrugBank/manufacturer sources
- TFDA package insert (warnings, contraindications) — currently a Blocking data gap (DG001)
- An independent mechanistic hypothesis or preclinical signal connecting antiviral monoclonal antibodies to tongue neoplasia before any further evaluation stage is warranted
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

